All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
The U.S. Food and Drug Administration has decided to place on hold clinical trial ATTCK-20-2 investigating an experimental T-cell therapy ACTR087 in combination with rituximab following lymphodepleting chemotherapy with fludarabine and cyclophosphamide in relapsed/refractory (R/R) CD20+ B-cell NHL (NCT02776813).
ACTR087, an autologous T lymphocytes expressing antibody coupled T-cell receptors (CD16V-41BB-CD3ζ), is also in clinical development in combination with SEA-BCMA in multiple myeloma (NCT03266692).
The FDA decision was brought by a recent report of serious adverse events including grade 3 neurotoxicity, cytomegalovirus infection, and grade 4 respiratory distress in one patient in the safety expansion cohort of the trial.
It is the second time that this phase I trial has been put on clinical hold due to the safety concerns. Previously, one patient died after suffering neurotoxicity related to ACTR087 events and another two patients suffered cytokine release syndrome before dying of sepsis. Before re-starting the trial changes were made to the protocol and dosing to reduce the incidence of adverse events.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox